|Fuminori Yoshida||Representative Director and President
Chief Executive OfficerDetails
|Kenji Murata||Board Director
Chief Financial Officer
Head of Corporate Planning and Administration DivisionDetails
|Shigetoshi Matsumoto||Board Director<Outside>Details|
|Bruce David Cheson||Board Director<Outside>Details|
|Rockford Douglas Norby||Board Director<Outside>Details|
|Kiyoshi Watanabe||Full-Time Audit & Supervisory Board Member<Outside>Details|
|Kesao Endo||Audit & Supervisory Board Member<Outside>Details|
|Eiji Ebinuma||Audit & Supervisory Board Member<Outside>Details|
| Fuminori Yoshida
Representative Director and President
Chief Executive Officer
|Fuminori Yoshida established SymBio Pharmaceuticals Limited, his third company, in March of 2005 in order to address the unmet medical needs of Japanese patients; as founding President of two other major healthcare companies, Nippon BioRad Laboratories (1980) and Amgen Japan (1993), he has earned high visibility and credibility within Japan's healthcare and academic communities. Following his graduation from Gakushuin University in 1971 with a B.S. in Organic Chemistry, he went on to receive an M.S. in Molecular Biology from MIT (1973) and M.S. in Health Policy and Management from Harvard University Graduate School (1975). He possesses dual experience and expertise in the management of major Japanese and American corporations through his work for various companies in the past, such as Mitsubishi Corporation and AHS Japan, Syntex Japan (1993) as President and CEO, serving concurrently at Amgen Japan (presently, Takeda Bio Development Center Ltd.) as President and CEO, and Amgen Inc. as Corporate Vice-President for 12 years until January of 2005. He has retained a high profile within the pharmaceutical industry due to his active involvement in various conferences (e.g. keynote speaker at 1st Bio-Expo), as member of several committees sponsored by the Ministry of Science and Technology, as lecturer at several prestigious colleges (e.g. Waseda University), as author of various publications in reputable pharmaceutical business journals, and as author of two books which were subsequently published in Japan (‘Golden DNA Helix' and ‘A Story of a Biotech Pioneer'). Utilizing his extensive management experience and social network, he has assembled an exceptional management team at SymBio.|
Chief Financial Officer
Head of Corporate Planning and Administration Division
|Kenji Murata graduated from the University of Tokyo with a bachelor's degree of law in 1991 and then joined Sumitomo Life Insurance Company. He completed a master's degree of business administration at Duke University in 1997. After joining Novartis Pharma K.K. in 2004 he held various important positions such as Strategic Sourcing Manager, Head of Oncology Finance & Administration, and Country CFO of Animal Health business. He also served as Country CFO of Elanco Japan at Eli Lilly (2015). He joined SymBio Pharmaceuticals Limited in December 2016 as Head of Finance and Accounting of the Company, and he became Corporate Officer, CFO in March 2018 and Head of Corporate Planning and Administration Division in October 2018. He currently serves as Board Director, Chief Financial Officer and Head of Corporate Planning and Administration Division from March 2019.|
|Shigetoshi Matsumoto graduated from University of Toyama Faculty of Pharmacy and Pharmaceutical Sciences in 1972, and then joined CHUGAI PHARMACEUTICAL CO., LTD. After holding various positions in Sales & Marketing related divisions, he assumed the position of General Manager of the Audit Office (2002),
At the Company, he has successively held the positions of Full-time Audit & Supervisory Board Member (2007), and Senior Advisor (2011). He became Advisor to APO PLUS STATION Co., Ltd. in 2011, and then became Senior Advisor to Protiviti LLC in 2015. He served as a member of the Audit & Supervisory Board at the Company in 2017.
He currently serves as Audit Practice Counselor, Japan Audit & Supervisory Board Members Association.
|Bruce David Cheson
|Dr. Cheson received his medical degree from Tufts University and completed his residency at University of Virginia Hospitals (1971) and fellowship at New England Medical Center Hospital (1974). Then he assumed Assistant Professor of Medicine, Hematology/Oncology of University of Utah School, University of Utah Hospital (1977), and Senior Investigator and Head of Medicine Section, National Cancer Institute, Cancer Therapy Evaluation Program (1984). He joined Georgetown University Hospital, Lombardi Comprehensive Cancer Center as Deputy Chief, Hematology-Oncology, Head of Hematology (2002), and became Frank M. Ewing Foundation Chair in Hematology-Oncology since 2018, Scientific Advisory Board, Lymphoma Research Foundation since 2001. He is currently the external board of directors of Morphosys since 2016, and he serves as Board Director of the company since March 2019.|
|Rockford Douglas Norby
|Rockford Douglas Norby graduated from Harvard University and completed a Harvard Business School in 1959, and then he served as Senior Vice President and Chief Financial Officer of Syntex Corporation (1979), and as President and Chief Operating Officer of Lucasfilm (1985).
He held various executive positions such as Board of director, Executive Vice President of LSI Logic Corporation (1996), Director and Chair of the Audit Committee, Lead Independent Director of Alexion (1999) and Chairman of the Board of MagnaChip Semiconductor (2010). He is currently the lead independent director and audit committee chair at Krystal Biotech, Inc. since 2017 and Board Director of the company since March 2019.
Full-Time Audit & Supervisory Board Member<Outside>
|Kiyoshi Watanabe graduated from Hitotsubashi University Faculty of Commerce and Management in 1974, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He completed a Master's degree (MSM) at Purdue University Krannert School of Management. After serving as Chief of The Americas Corporate Credit Office, Credit Department of the Bank from 1998 in New York, he joined Kyowa Hakko Kogyo Co., Ltd. in 2003 as General Manager, Corporate Planning Office. He became General Manager, Medicine Planning Department of the Company in 2005, and then became General Manager, Planning and Administration Department at KYOWA HAKKO BIO CO., LTD. in 2008. He assumed the position of Full-time Audit & Supervisory Board Member at Kawaguchi Chemical Industry Co., Ltd. in 2011 and Audit & Supervisory Board Member at Toho Acetylene Co., Ltd., in 2015.|
Audit & Supervisory Board Member<Outside>
|Kesao Endo received his certification as a Certified Public Accountant in 1983. He joined Price Waterhouse Consultant in 1984. He joined Deloitte and Touche in 1986 and was stationed at Deloitte's Los Angeles and New York offices. He earned his USPCA (United States Certified Public Accountant) in 1991. He served as a member of the Audit & Supervisory Board at Akebono Brake Industry Co., Ltd in 2006. He currently serves outside director of Careerlink Co., Ltd. and is a partner of ABS Audit Corporation.|
Audit & Supervisory Board Member<Outside>
|Eiji Ebinuma graduated from the Faculty of Law, the University of Tokyo in 1980, and completed a Master's degree in law at Sophia University. He joined The Industrial Bank of Japan, Limited (currently Mizuho Bank Ltd.) in 1980 and promoted to Deputy Head of HR Planning Team of Mizuho Bank, Ltd (2002), and then he assumed the position of Head of Executive Secretary and General Planning Dept. of Olimpic Corporation (2003). He received his certification as a lawyer and joined Toranomon Sougoh Law Firm in 2008, and he served as the Partner at Tanabe & Partners from 2013. He is currently the Board of Director of Mirait Holdings and Rakuten Bank Ltd, and Board Director of the company since March 2019.|